Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Idenix
So what: Pharmasset's experimental hepatitis C drug PSI-938 reported complications with liver function, although the developments aren't expected to interfere with Gilead Sciences'
Now what: The news is causing concern among some hepatitis C drugmakers, including Inhibitex
Interested in more info on Idenix? Add it to your watchlist by clicking here.